An anonymous director reports

APOTEX HEALTH CORP. ANNOUNCES CLOSING OF $1,250 MILLION INAUGURAL SENIOR UNSECURED NOTES OFFERING

Apotex Health Corp. has closed the previously announced offering of $1,250-million aggregate principal amount of senior unsecured notes in three series, consisting of $400-million aggregate principal amount of 4.390 per cent senior unsecured notes, Series 1, due Oct. 5, 2029, $550-million aggregate principal amount of 4.769 per cent senior unsecured notes, Series 2, due Oct. 5, 2031, and $300-million aggregate principal amount of 5.133 per cent senior unsecured notes, Series 3, due Oct. 5, 2033. The offering was made through a syndicate of agents led by RBC Capital Markets, BMO Capital Markets, Scotiabank and TD Securities, as joint bookrunners, and ATB Cormark Capital Markets, CIBC Capital Markets and National Bank of Canada Capital Markets, as co-managers.

The notes are direct, senior, unsecured obligations of the company, ranking equally with all other senior unsecured and unsubordinated indebtedness of the company. The notes are jointly and severally guaranteed on a senior unsecured basis by certain subsidiaries of the company. Apotex will use the net proceeds of the offering to refinance existing indebtedness and for other general corporate purposes. The notes were sold by way of a private placement in each of the provinces of Canada with reliance upon exemptions from the prospectus requirements under applicable securities laws. On July 16, 2026, the company received an inaugural investment-grade issuer rating of BBB (Low) with a stable outlook from Morningstar DBRS. The notes have also been assigned a rating of BBB (Low) with a stable outlook from Morningstar DBRS.

About Apotex Health Corp.

Apotex is a Canadian-based global health company. The company improves everyday access to affordable, innovative medicines and health products for millions of people around the world, with a broad portfolio of generic, biosimilar and innovative branded pharmaceuticals, and consumer health products. Headquartered in Toronto, with regional offices globally, including in the United States, Mexico and India, the company is the largest Canadian-based pharmaceutical company and a health partner of choice for the Americas for pharmaceutical licensing and product acquisitions.

We seek Safe Harbor.